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administration of 5.0µM and 10.0µM (three times daily for three days) 
significantly reduced keratitis. The mean clinical scores were 3.3±0.58 
and 2.3±0.50 for 5.0µM and 10.0µM treatments respectively com-
pared to 4.0±0.0 for the vehicle control (p<0.001). In addition, 4.3±0.6 
log10 and 3.9±1.3 log10 viable P. aeruginosa was recovered from the 
5.0µM and 10.0µM VR18 treated eyes respectively compared to 
6.1±0.9 log10 recovered from the control eyes (p<0.001). Overall, our 
findings indicate that VR18 is a promising candidate for the develop-
ment as a novel topical antibiotic against Pseudomonas keratitis.
Figure 1: Representative photographs of the development of corneal infection following scratch and 
instillation of P. aeruginosa 6294 bacteria in the (A-D) vehicle control, (E-H) 5µM VR18 and (I-L) 10 µM 
VR18 treatment groups at day three. 
1. Mohid, S.A.; Ghorai, A.; Ilyas, H.; Mroue, K.H.; Narayanan, G.; Sarkar, A.; 
Ray, S.K.; Biswas, K.; Bera, A.K.; Malmsten, M., et al. Colloids Surf B Bioint-
erfaces 2019, 176, 360-370, doi:10.1016/j.colsurfb.2019.01.020.
R7: Antimicrobial properties of cell penetrating 
peptides against Mycobacterium smegmatis: Potential 
therapeutics for tuberculosis disease management
Pankhuri Narula, Archana Chugh*, Anjali Priya, Anusha Adit-
ya, Deepthi P Budagavi
Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, 
New Delhi, India 110016; achugh@bioschool.iitd.ac.in
Cell penetrating peptides (CPPs) are a class of cationic peptides that 
are able to translocate themselves across cellular membranes and 
also carry cargo molecules with them, much larger than their own 
size. They have been reported to possess dual characteristics of cell 
penetration as well as antimicrobial activity [1]. The mode of action of 
these peptides can be direct membrane lysis or intracellular target-
ing of crucial metabolic pathways. Tuberculosis (TB) is one of the 
most devastating diseases in the world with a global disease burden 
of 10 million people. It is a matter of grave concern since available 
antibiotics are becoming ineffective for treatment due to emergence 
of drug resistant strains [2]. Among developing countries, India has 
the highest incidence rate of TB. It also comes under 30 high burden 
countries listed with occurrences from all the three categories: TB, 
multi drug resistant-TB and TB-HIV co-infection. In the present study, 
antimicrobial activity of two CPPs, Tachyplesin and CyLoP-1 (derived 
from marine horseshoe crab and snake venom respectively) was evalu-
ated against Mycobacterium smegmatis. The antimicrobial potency of 
peptides against M. smegmatis was determined by Minimum inhibito-
ry concentration (MIC) evaluation. The peptides significantly reduced 
the bacterial count at their specific concentrations and time points. 
The peptides were also assessed for their qualitative and quantitative 
uptake in macrophage cells and their biocompatibility towards them. 
Furthermore, mechanisms of antimicrobial action of CPPs were deter-
mined using various microscopic and fluorescence techniques as well 
as membrane depolarization, ROS production assays. By analyzing 
all these aspects of CPPs antimicrobial action against M. smegmatis, a 
potential alternative therapeutics can be developed for effective tuber-
culosis disease management.
[1] Budagavi, D. P. & Chugh, A. European Journal of Pharmaceutical.115, 
43–49 (2018); [2] Floyd, K., Glaziou, P., Zumla, A. & Raviglione, M. The 
Lancet Respiratory Medicine 6, 299–314 (2018).
L32: Discovery and development of SPR206: a next 
generation polymyxin analogue
Michael J Dawson
Spero Therapeutics, Cambridge MA, USA
Polymyxins are an important class of antibiotics for therapy of 
Gram-negative infections, but their efficacy is limited by toxicities, 
especially renal toxicity. The main physicochemical drivers for toxici-
ty are the same as the drivers for efficacy i.e. charge and lipophilicity. 
Nevertheless, the molecular mechanisms for activity and toxicity are 
undoubtedly different and careful empirical dissection of the struc-
ture-activity relationships for each has allowed the development of 
next generation analogues with retained, or improved, antimicrobial 
activity and reduced toxicity. One promising analogue, SPR206, 
exhibits reduced renal toxicity compared to polymyxin B in Cyno-
molgus monkey and is currently undergoing a phase I trial in human 
volunteers. 
L33: Snake cathelicidins are highly effective against 
antimicrobial resistant bacteria and particular 
tumours
Nibbering PH1, Kerkkamp HMIJ2, Voet MM1, Verhagen JAM1, 
Heemskerk D1, Gilson AD1, Cordfunke RA3, Verdegaal EME4, 
Drijfhout JW3, Richardson MK2, and van Wezel GP2
Depts. of 1 Infectious Diseases, 3 Immunohematology and Blood Trans-
fusion, and 4 Medical Oncology, Leiden University Medical Centre, and 2 
Institute of Biology, Leiden University, Leiden, the Netherlands; p.h.nibber-
ing@lumc.nl.
Bacterial infections that are hard-to-treat due to antimicrobial 
resistance (AMR), as well as cancer, are major public health threats 
worldwide. Novel agents to combat these threats are urgently needed. 
As animal venoms have been the origin of several major drugs with 
anticancer and/or antimicrobial activity, we mined the genomes of 
19 snake species for a class of antimicrobial peptides, i.e. catheli-
cidins, and synthesized 37 different snake peptides. To select the most 
promising peptides, we first tested all peptides for their bactericidal 
activity against AMR Staphylococcus aureus (MRSA), Acinetobacter 
baumannii and Pseudomonas aeruginosa and for their haemolytic 
activity. Further testing of the two peptides most promising in having 
excellent antimicrobial activity and negligible cytotoxicity revealed 
that they rapidly and effectively (sub-μM concentrations) kill AMR 
Gram-negative bacteria without affecting the viability of human 
erythrocytes (therapeutic index ≥500). The lead peptides were highly 
effective in killing AMR ESKAPE bacteria and colistin-resistant Es-
cherichia coli in whole human blood. Importantly, these peptides did 
not induce resistance in vitro in AMR E. coli and A. baumannii using 
40 serial cycles, were more effective in degrading AMR A. baumannii 
biofilms than MRSA biofilms and prevented biofilm formation by 
both bacteria in a dose-dependent fashion. Furthermore, lead peptides 
dose-dependently eliminated MRSA and AMR A. baumannii from 
wounded ex vivo human skin models. Finally, lead snake peptides 
were selectively cytotoxic to melanoma, renal cell carcinoma, and 
cervical carcinoma cell lines compared to normal melanocytes and fi-
broblasts, but not against ovarian epithelial cell carcinomas, colorectal 
carcinoma and breast ductal carcinoma cell lines compared to normal 
fibroblasts. Additional experiments indicated that snake peptides in-
duce apoptosis, as measured by caspase 3/7 activation, in tumour cell 
lines. Together, these in vitro data indicate that lead snake peptides 
have potential as novel agents for systemic and topical treatment of 
patients with AMR infections and some tumours. 
Poster Abstracts
P1: A placenta derived fragment of β-hemoglobin 
with antibacterial activity
Richard Bauer,1 Franziska Krüger,2 Rüdiger Groß,2 Ludger 
Ständker,3 Nico Preising,3 Paul Walther,4 Jan Münch2 and 
Barbara Spellerberg1
1 Institute of Medical Microbiology and Hygiene; 2 Institute of Molecular Vi-
rology; 3 Core Facility Functional Peptidomics; 4 Central Facility for Electron 
Microscopy, Ulm University, Ulm, Germany; richard.bauer@uni-ulm.de
Human hemoglobin is a rich source of bioactive cryptides with 
antimicrobial activity [1]. To identify and characterize bioactive 
human peptides, peptide libraries of placenta tissue were generated 
by chromatography and screened for antimicrobial activity against 
various bacterial pathogens. Fractions with the highest antimicrobial 
activity harboured large amounts of a fragment of the human β-hemo-
globin [HBB(111-146)], a bioactive peptide that has previously been 
characterized [2]. The purified HBB(111-146) showed a concentration 
dependent activity against different Pseudomonas aeruginosa stains 
of clinical origin and it was able to inhibit the growth of a Carbap-
enem resistant P. aeruginosa isolate that harbors a KPC-2 carrying 
plasmid [3]. Growth inhibition could already be observed at a peptide 
concentration of 15.63 µg ml-1, a concentration markedly lower than 
the described concentration of HBB(111-146) in the placenta (280-740 
µg ml-1) [4]. Moreover we could demonstrate that HBB(111-146) 
permeabilizes the cell membrane of P. aeruginosa using Sytox green 
staining and we could observe membrane disintegration in electron 
microscopic investigations. In the presence of low pH the aspartyl pro-
tease Cathepsin D generates HBB(111-146) from the precursor hemo-
globin. Under similar acidic conditions the peptide exhibits its highest 
antimicrobial activity against P. aeruginosa in liquid medium. Thus, 
we propose that under acidic conditions, a hallmark of inflammation 
and infection, HBB(111-146) can be generated from the precursor 
hemoglobin and exhibits broad antimicrobial activity potentially 
restricting diaplacental transmission of bacterial pathogens.
1 Mak, P. Front Biosci 13, 6859-6871 (2008); 2 Liepke, C. et al. J Chromatogr 
B Analyt Technol Biomed Life Sci 791, 345-356 (2003); 3 Hagemann, J. B., 
Pfennigwerth, N., Gatermann, S. G., von Baum, H. & Essig, A. J Antimicrob 
Chemother 73, 1812-1814, doi:10.1093/jac/dky105 (2018); 4 Standker, L. et al. 
Anal Biochem 401, 53-60, doi:10.1016/j.ab.2010.02.019 (2010).
P2: A novel antimicrobial peptide produced by 
the environmental bacterial isolate Paenibacillus 
polymyxa displays broad-spectrum activity in the 
Galleria mellonella larvae model
Vicky Bennett, Garry Farnham, Mathew Upton
School of Biomedical Sciences, University of Plymouth, Plymouth, UK
Introduction: The Galleria mellonella (G.mellonella) larvae infection 
model is a reliable tool for early in vivo screening of antimicrobial 
compounds without the ethical constraints of mammalian models [1]. 
This model was therefore used to test an as yet unidentified antimicro-
bial peptide (36A90) isolated from the environmental bacterial isolate 
Paenibacillus polymyxa, which had previously shown broad-spectrum 
activity in vitro.
Methods: To assess toxicity, G.mellonella larvae were injected with 
purified 36A90 at a dose of 24mg/kg. To assess antimicrobial efficacy, 
larvae were first infected with the LD50 of either Escherichia coli 
(E.coli) or methicillin-resistant Staphylococcus aureus (MRSA), fol-
lowed by treatment with 36A90 at a dose of 24mg/kg at intervals of 15 
minutes-2 hours post infection. For both the toxicity and efficacy ex-
periments, all larvae were incubated at 37ºC, with survival monitored 
for 120 hours. The in vivo stability of the compound was measured by 
assessing the antimicrobial activity of the extracted haemolymph of 
treated larvae over incubation periods of 0-24 hours.
Results: Preliminary compound characterisation, and examination 
of the draft genome sequence of the producing strain indicates that 
36A90 is a novel peptidic compound. The 24mg/kg dose significantly 
improved the survival rate of E.coli infected larvae at all post-infec-
tion treatment intervals, and the MRSA infected larvae at a treatment 
interval of up to 30 minutes. 36A90 showed in vivo stability in the 
haemolymph assay for up to 4 hours. 
Conclusion: This model has demonstrated the early potential of com-
pound 36A90. Cell toxicity studies are ongoing, as is identification 
and structural characterisation.
[1] Andrea, A., Krogfelt, K., and Jenssen , H. (2019) Microorganisms, 7(85)
P3: Study on the influence of bacterial 
lipopolysaccharides on the secondary structure of 
antimicrobial peptides, in free-form and conjugated 
with polymeric linkers, using circular dichroism 
spectroscopy.
Marc Bruggeman, ; Hanieh Ijakipour, and Artemis Stamboulis
Biomaterials Group, School of Metallurgy and Materials, University of 
Birmingham, UK; MXB1082@student.bham.ac.uk
Antimicrobial peptides (AMPs) are a part of the innate immune 
system’s response to foreign organisms in the body [1]. Being a part of 
the innate immune system, these peptides are non-specific and hence 
a solution to antimicrobial resistance. Therefore, they can be used to 
target many different pathogenic organisms such as bacteria, fungi and 
viruses. After an initial lack of interest by the pharmaceutical industry, 
several AMPs are now being investigated in clinical trials [2-3]. In 
free-form, AMPs can recognise and disrupt microbial membranes 
through numerous mechanisms [4]. However, AMPs in free-form can 
be readily metabolized within the body and lose their antimicrobial 
activity [5]. Conjugation of AMPs with polymeric linkers can improve 
the AMPs’ life-time and stability in the physiological environment but, 
may affect the secondary structure and thus activity of the conjugated 
AMP [6]. Previous studies highlight the significance of the secondary 
structure of AMPs, relating to their antimicrobial activity and cytotox-
icity [7]. Therefore, the effect of polymer conjugation and interfacial 
interactions between AMPs and microbial membranes needs to be 
understood. In order to study these interactions, bacterial lipopoly-
saccharides are added to AMP solutions and analysed with circular 
dichroism spectroscopy – using AMPs in free-form and conjugated 
with polymeric linkers. This study is fundamental to design AMPs 
with desirable secondary structures, improving their performance in 
future developments.
[1] Diamond, G., Beckloff, N., Weinberg, A., & Kisich, K. O. (2009). The 
roles of antimicrobial peptides in innate host defense. Current pharmaceutical 
design, 15(21), 2377-2392; [2] E Greber, K., & Dawgul, M. (2017). Antimicro-
bial peptides under clinical trials. Current topics in medicinal chemistry, 17(5), 
620-628; [3] Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016). 
Antimicrobial peptides: an emerging category of therapeutic agents. Frontiers 
in cellular and infection microbiology, 6, 194; [4] Guilhelmelli, F., Vilela, 
N., Albuquerque, P., Derengowski, L., Silva-Pereira, I., & Kyaw, C. (2013). 
Antibiotic development challenges: the various mechanisms of action of 
antimicrobial peptides and of bacterial resistance. Frontiers in microbiology, 4, 
353; [5] Marr, A. K., Gooderham, W. J., & Hancock, R. E. (2006). Antibacteri-
al peptides for therapeutic use: obstacles and realistic outlook. Current opinion 
in pharmacology, 6(5), 468-472; [6] Bagheri, M., Beyermann, M., & Dathe, M. 
(2009). Immobilization reduces the activity of surface-bound cationic antimi-
crobial peptides with no influence upon the activity spectrum. Antimicrobial 
agents and chemotherapy, 53(3), 1132-1141; [7] Mai, X. T., Huang, J., Tan, 
J., Huang, Y., & Chen, Y. (2015). Effects and mechanisms of the secondary 
structure on the antimicrobial activity and specificity of antimicrobial peptides. 
Journal of Peptide Science, 21(7), 561-568.
P4: Identification of a new antifungal peptide against 
grapevine downy mildew
M. Colombo1, S. Masiero2, M. Perazzolli1, S. Pellegrino3, R. Ve-
lasco4, R. Musetti5, S. L. Toffolatti6, S. Vezzulli1, P. Pesaresi2
1 Research and Innovation Centre, Fondazione Edmund Mach, San Michele 
all’Adige, Italy; 2 Department of Biosciences and 3 Department of Phar-
maceutical Sciences, University of Milano, Milano, Italy; 4 CREA, Research 
Centre for Viticulture and Enology, Conegliano, Italy; 5 Department of 
Agricultural, Food, Environmental and Animal Sciences, University of Udine, 
Udine, Italy; 6 Department of Agricultural and Environmental Sciences 
- Production, Landscape, Agroenergy, University of Milano, Milano, Italy; 
monica.colombo@fmach.it
The biggest challenge global agricultural production is currently fac-
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ing is the secure and sustainable supply of food for a constantly grow-
ing human population. Increasing agricultural productivity through 
the prevention of crop yield losses due to biotic stresses has therefore 
assumed considerable urgency. Modern agriculture strongly relies on 
pesticides to avoid losses and produce high-quality foods. Fungicides 
in particular represent the majority of plant protection products, with 
viticulture representing one of the first sector in terms of fungicide 
usage which has a serious negative impact on the environment and 
on human/animal health. As a consequence, crop protection is now 
oriented towards a rational use of pesticides and the development of 
eco-friendly pesticide alternatives. Among the available biotechno-
logical solutions, peptide aptamers, i.e. artificial, high-affinity short 
peptides that specifically inhibit a target molecule through protein 
interference, are emerging as novel molecular tools.
Grapevine downy mildew, caused by the oomycete Plasmopara vitico-
la (Berk. & Curt.) Berl. & de Toni, is a worldwide destructive disease 
of primary importance for viticulture. Within the frame of Grapta-
Resistance research project (https://sites.unimi.it/graptaresistance/), 
we identified a novel peptide aptamer, named NoPv1 (No P. viticola 
1), able to counteract P. viticola infection ex vivo (leaf disks) and in 
vivo (potted plants). NoPv1 has been isolated from a peptide library, 
through the yeast two-hybrid strategy, using the PvCesA2 protein (P. 
viticola cellulose synthase 2) as a bait. In addition, we demonstrated 
that NoPv1 targets specifically P. viticola as well as Phytophtora 
infestans, without affecting off-target organisms and being toxic for 
human cells.
P5: Design and development of short and stable 
pepR-derived antibacterial peptides
A. F. Cruz,1 J.M. Freire,1 S. N. Pinto,2 A. Coutinho,2,3,4 D. Andreu,5 
J. Valle,5 M. A. R. B Castanho,1 A. S. Veiga1
1 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade 
de Lisboa, Lisboa, Portugal; 2 Centro de Química-Física Molecular e IN, 
Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal; 3 iBB 
- Institute for Bioengineering and Biosciences, Department of Bioengineer-
ing, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal; 4 
Departamento de Química e Bioquímica, Faculdade de Ciências, Univer-
sidade de Lisboa, Portugal; 5 Department of Experimental and Health 
Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, 
Barcelona, Spain; ana.cruz@medicina.ulisboa.pt
The increasing number of bacterial infections and resistance to exist-
ing antibiotics has become a global health problem. Although antimi-
crobial peptides (AMPs) have been considered promising alternatives 
to conventional antibiotics, one of the main limitations hindering 
their use as therapeutic drugs is the high susceptibility to proteolytic 
degradation. Here, we used pepR, a peptide with known antibacterial 
activity, as a starting sequence to develop short and stable antibacte-
rial peptides. Twelve pepR-derived peptides were obtained through 
sequential truncations performed on each terminus of pepR sequence. 
The deletion of amino acid residues at the C-terminus significantly 
impaired the antibacterial activity, which is correlated with the lack 
of ability of the peptides to adopt an alpha-helical conformation. The 
shortest peptide with highest antibacterial activity – N6-pepR, caused 
a fast killing of Staphylococcus aureus through bacterial membrane 
permeabilization. However, antibacterial activity was lost after only 1 
h incubation in presence of human serum. Through the use of rational 
design two new peptides able to retain antibacterial activity even after 
24 h incubation with serum were obtained. Overall, the work devel-
oped not only resulted on the discovery of two peptides with high 
antibacterial activity and proteolytic resistance, but also gives insights 
on the physicochemical properties that can be engineered to improve 
the application of AMPs as therapeutic drugs.
P6: Integrated evolutionary analysis reveals 
antimicrobial peptides with limited resistance 
Lejla Daruka1,2, Réka Spohn1, Viktória Lázár1, Ana Martins1, 
Fanni Vidovics1, Gábor Grézal3,1, Orsolya Méhi1, Bálint Kintses1, 
Mónika Számel1,2, Pramod K Jangir1,2, Bálint Csörgő1, Ádám 
Györkei3,1, Balázs Papp3,1, Csaba Pál1
1 Synthetic and Systems Biology Unit, Institute of Biochemistry, Biological 
Research Centre, Hungarian Academy of Sciences, Szeged, Hungary; 2Doc-
toral School of Biology, Faculty of Science and Informatics, University of 
Szeged, Szeged, Hungary; 3 HCEMM-BRC Metabolic Systems Biology Lab
Antimicrobial peptides (AMPs) are promising novel antimicrobials, 
however, the potential of bacterial resistance is a major concern. Here 
we systematically study the evolution of resistance to a chemically 
diverse set of AMPs and small-molecule antibiotics in Escherichia 
coli. Four lines of evidence indicate that, compared to antibiotics, the 
evolution of resistance against some AMPs is frequently limited. First, 
no clinically significant resistant mutants have emerged in laboratory 
evolution tests against certain AMPs. Second, drug-resistant bacteria 
have displayed no cross-resistance to these AMPs. Third, gene am-
plification, an important genetic source of antibiotic resistance, does 
not influence resistance to these AMPs. Finally, genomic fragments 
derived from a wide range of soil bacteria confer no detectable resist-
ance against these AMPs when introduced into native host bacteria on 
plasmids. We have found that simple physicochemical features dictate 
bacterial propensity to evolve resistance against AMPs. Our work 
could serve as a promising source for the development of AMP-based 
new therapeutics less prone to resistance, a feature necessary to avoid 
any possible interference with our innate immune system.
P7: The investigation of bacteria isolated from deep-
sea sponges for the development of novel antibiotics
Lena Faller1, Mathew Upton2, Matthew Koch2, Poppy Best2, 
Vicky Bennet3, Florie Desriac2, Kerry Howell4
1 University of Applied Sciences FH Campus Wien, Department Applied Life 
Sciences, Vienna, Austria; 2 University of Plymouth, School of Biomedical 
Sciences, Plymouth, UK; 3 University of Bath, Department of Pharmacy and 
Pharmacology, Bath, UK; 4 University of Plymouth, School of Biological and 
Marine Sciences, Plymouth, UK; lenafaller17@gmail.com
Bacteria isolated from deep-sea creatures, like sponges, have a high 
potential to produce novel antibiotics as the deep-sea environment is 
relatively unexplored with very different conditions to those on the 
earth’s surface. After the bacterial isolation from a deep-sea sponge 
of the genus Pheronema, one of the isolates showed antimicrobial 
activity against gram-positive and gram-negative bacteria and was 
therefore selected for further experiments. The gram-positive isolate 
was characterised by 16S rDNA sequencing and a possible relation 
to the genus Domibacillus was shown. The antimicrobial, purified by 
chromatography, was identified as a protein and its thermostability 
between -20°C and 56°C was shown. The antimicrobial compound 
was successfully tested against multiple clinically relevant indicator 
strains, including meticillin-resistant Staphylococcus aureus (MRSA) 
and vancomycin-resistant enterococci. Additionally, the minimal 
inhibitory concentration was determined for Klebsiella pneumonia, 
Salmonella typhimurium and Escherichia coli as 29 μg/ml and for 
S. aureus and MRSA as 7.25 μg/ml. Toxicity testing in Galleria 
mellonella showed that the compound is non-toxic in a dose of at least 
2.45 mg/kg. Therefore, the antimicrobial compound has shown poten-
tial to be a promising candidate for a novel antibiotic, which could be 
used to tackle the antimicrobial resistance crisis.
P8: First Confirmation of Nisin P Structure
Enriqueta Garcia-Gutierrez1,2, Gerhard Saalbach3, Paula M. 
O’Connor2,4, James W. Hegarty2,4, Melinda J. Mayer1, Arjan 
Narbad1 and Paul D. Cotter2,4
1 Gut Microbes and Health, Quadram Institute Bioscience, Norwich, UK; 2 
Food Bioscience, Teagasc Moorepark, Fermoy, Ireland; 3 Biological Chem-
istry, John Innes Centre, Norwich, UK; 4 APC Microbiome Ireland, University 
College Cork, Cork, Ireland; enriqueta.garcia@quadram.ac.uk.
Nisin is a small peptide with antimicrobial activity against a wide 
range of pathogenic bacteria. Nisin is classified as a bacteriocin 
class I, because it is ribosomally synthesised and post-translationally 
modified. More specifically, nisin is considered a lantibiotic because it 
contains lanthionine (Lan), an unusual amino acid formed by two ala-
nine residues linked by a sulphur atom through their β-carbon. Other 
unusual amino acids present in nisin are dehydroalanine (Dha), dehyd-
robutyrine (Dhb) and β-methyl-lanthionine [1]. Nisin has nine natural 
variants that have been reported at the moment, including nisin P. The 
Nisin P operon was previously identified in the genomes of two Strep-
tococcus species [2, 3]. However, its production has not been reported 
before. We found that nisin P is produced by another Streptococcus 
sp and here, and we analysed its structure by nanoLC-MS/MS. The 
trypsinization of nisin P gave 13 exclusive unique spectra of 78 total 
spectra, with 19 out of 31 amino acids being represented with 99% 
probability. Using this technique, we confirm the presence of rings A, 
C and D, while rings B and E were found in approximately 50% of the 
chemical species, based on the presence of carbamido-methylations 
that were observed in modified cysteine residues. Thus, we confirmed 
the previously predicted structure of nisin P. 
1. Gharsallaoui, A., N. Oulahal, and C. Joly. Crit Rev Food Sci Nutr, 
2016. 56; 2. Zhang, Q., et al. Proceedings of the National Academy of 
Sciences of the United States of America, 2012. 109 (45): p. 18361-
18366; 3. Wu, Z., et al. Gene, 2014. 535(2): p. 156-164.
P9: Isolation of antimicrobial compounds from three 
bacteria recovered from deep-sea glass sponges
Poppy J. Hesketh Best1, Matthew Koch2, Alistair Bishop1, Nico-
la Foster1, Phillip Warburton2, Kerry Howell1, Mathew Upton2
1 Faculty of Biology and Marine Sciences, and 2 Faculty of Medicine and 
Dentistry, University of Plymouth, Plymouth, UK; 
poppy.heskethbest@plymouth.ac.uk 
The holobionts of deep-sea sponges are attracting attention as a 
source of novel antimicrobial compounds, with cultivation-dependent 
approaches yielding promising results [1,2]. In screening biological 
samples from hard-to-reach habitats, such as the deep-sea, it may pos-
sible to improve the discovery of unique compounds. In this project, 
two species of deep-sea sponge were sampled from the North Atlantic 
at 1.5 – 2.8 km deep. 
Three bacterial isolates (PB091, RC230 and RE697) were recovered 
on R2a medium and were selected for detailed analysis. Compounds 
were purified using liquid chromatography (hydrophobic interaction 
chromatography and size exclusion) and investigated to identify the 
minimum inhibitory concentration against Gram-positive and -neg-
ative bacteria and in and Greater Wax moth larvae assays. Finally, a 
draft genome obtained for PB091 was assembled and annotated using 
Geneious Prime and analysed using the AntiSMASH-5.0 mining tools.
Compounds produced by strain PB091 demonstrated activity towards 
various methicillin resistant Staphylococcus aureus, while RC230 
and RE697 recovered compounds displayed broad spectrum activity 
against MRSA and Escherichia coli. Analysis of the draft genome of 
PB091 (6.7 Mbp) indicates that it is a member of the Delftia genus. 
AntiSMASH hits suggest the presence of antimicrobial peptide encod-
ing gene clusters.
Bacteria isolated from deep-sea sponges are a possible source of novel 
antimicrobial agents. Characterisation of the three isolates recovered 
here and the antimicrobial compounds thus far purified from them 
may reveal hits that warrant further development. Draft genomes 
will be obtained for all three isolates and metagenomic analysis of 
the sponge holobiome will facilitate identification of the uncultivable 
bacterial taxa and may reveal relevant antimicrobial production gene 
clusters.
[1] Xin YJ, Kanagasabhapathy M, Janussen D, Xue S & Zhang W (2011) Phy-
logenetic diversity of Gram-positive bacteria cultured from Antarctic deep-sea 
sponges. Polar Biol 34: 1501-1512.; [2] Xu D, Han L, Li C, et al. (2018) Bio-
prospecting deep-sea Actinobacteria for novel anti-infective natural products. 
Frontiers in microbiology 9: 787. 
P10: Plant foods as a source of antimicrobial peptides 
for food preservation
Marie-Louise Heymich1, Ulrike Friedlein2, Karin Schwaiger2 
and Monika Pischetsrieder1
1 Henriette Schmidt-Burkhardt Chair of Food Chemistry, Friedrich-Alexan-
der University Erlangen-Nuremberg, Erlangen Germany; 2 Chair of Food 
Safety, Faculty of Veterinary Medicine, Ludwig-Maximilian-University, 
Munich, Germany; marie-louise.heymich@fau.de
According to the World Health Organization (WHO), 350,000 deaths 
per year worldwide are related to foodborne diseases caused by bac-
teria, viruses, parasites, and/or toxins due to contaminated food [1]. 
Therefore, the identification of alternative preservatives affecting a 
wide range of microorganisms is of high importance.
The aim of the project was to obtain antimicrobial peptides from plant 
foods, which can be used as preservatives in food production. Since 
the antimicrobial peptides are derived from a food source, they are 
considered as non-toxic and compatible with the clean label strategy.
Thus, storage proteins were extracted from chickpeas and peptides 
were then generated by enzymatic hydrolysis with chymotrypsin. 
The resulting peptide profiles were comprehensively analyzed by 
ultra-performance micro-LC-ESI-TripleTOF-MS/MS. Antimicrobial 
candidates were identified by virtual screening using the Antimicrobial 
Peptide Database and structure prediction software like I-Tasser and 
Helical Wheel Projection. Main selection criteria were a positive net 
charge, the hydrophobic content, the ability to form an amphipathic 
helical structure and the water solubility. 21 antimicrobial peptide 
candidates were identified in the peptide profile of the chickpea 
storage protein legumin. Afterwards, the antimicrobial activity of the 
synthesized peptides was experimentally tested against 14 different 
pathogens. The peptides leg1 (RIKTVTSFDLPALRFLKL) and leg2 
(RIKTVTSFDLPALRWLKL) showed the lowest minimal inhibitory 
concentration (MIC) of 62.5 μM against Escherichia coli, 15.6 μM 
against Bacillus subtilis and 125 μM against Clostridium perfringens, 
Extended-Spectrum-Betalactamase building E. coli and Pseudomonas 
putida.
Consequently, leg1 and leg2 are antimicrobial peptides generated 
from chickpea legumin, which may be suitable to protect against food 
spoilage and foodborne infections.
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In 2016, the O’Neil report on antimicrobial resistance (AMR) reported 
50,000 deaths in Europe and the United States due to AMR bacterial 
infections [1]. There is an ever-growing gap between the available 
therapeutics and the increase in microbial resistance, particularly 
in gram negative bacteria. It is predicted that by 2050, there will be 
around 10 million deaths a year due to AMR infections [2]. E. coli 
is the most common gram negative bacterial infection in humans 
and in 2017, Enterobacteriaceae, mainly E. coli, comprised 84.4% 
of antibiotic resistant bloodstream infections [3]. Experimentally 
validated antibacterial peptides, up to 24mer in length, were selected 
from CAMP [4] and DRAMP [5] databases. Peptides were synthesised 
by SPOT-synthesis and screened against a multidrug resistant strain of 
Escherichia coli, with and without 10% human serum. High through-
put screening was done with resazurin and fluorescence was meas-
ured. Results were analysed by Gait-cad [6] and peptides were put into 
4 different activity levels depending on their IC75 when compared to 
a control peptide. 12 peptide sequences were selected for solid-phase 
resin synthesis, fully active in 10% serum, fully active without serum 
and peptides with weak activity to validate screening. Here we report 
results from minimum inhibitory concentrations assays, with 0%, 10% 
and 25% human serum, against a clinical isolate of multidrug resistant 
E. coli and other strains of multidrug resistant bacteria and time kill 
